August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS31
Academic Journal
Presents an abstract of the research manuscript `Hematopoietic stem cell transplantation (HSCT) for progressive intermediate grade non-Hodgkin's lymphoma,' by A.L. Watson, M.J. Barnett et al from the University of British Columbia.


Related Articles

  • Failure of front-line autologous transplant in anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma. Holtan, S. G.; Feldman, A. L.; Knudson, R. A.; Ketterling, R. P.; Porrata, L. F. // Bone Marrow Transplantation;Jun2011, Vol. 46 Issue 6, p904 

    A letter to the editor is presented regarding the ineffectiveness of front-line autologous hematopoietic stem cell transplantation (SCT) to treat anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL).

  • Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Kim, S-W; Yoon, S-S; Suzuki, R; Matsuno, Y; Yi, H G; Yoshida, T; Imamura, M; Wake, A; Miura, K; Hino, M; Ishikawa, T; Kim, J S; Maeda, Y; Lee, J-J; Kang, H J; Lee, H S; Lee, J-H; Izutsu, K; Fukuda, T; Kim, C W // Leukemia (08876924);Jun2013, Vol. 27 Issue 6, p1394 

    A letter to the editor is presented in response to the article on the outcomes of allogeneic and autologous hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology.

  • Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support. Milpied, Noel; Deconinck, Eric; Gaillard, Fanny; Delwail, Vincent; Foussard, Charles; Berthou, Christian; Gressin, Remy; Lucas, Virginie; Colombat, Philippe; Harousseau, Jean-Luc // New England Journal of Medicine;3/25/2004, Vol. 350 Issue 13, p1287 

    Background: The efficacy of first-line intensive chemotherapy plus transplantation of autologous hematopoietic stem cells in adults with disseminated aggressive lymphoma is unknown. Methods: We compared high-dose therapy plus autologous stem-cell support with the standard regimen of...

  • The Future of Placental-Blood Transplantation. Parkman, Robertson // New England Journal of Medicine;11/26/98, Vol. 339 Issue 22, p1628 

    Editorial. Discusses an article by Rubinstein and his colleagues in the November 26, 1998 issue of the `New England Journal of Medicine' dealing with a study of allogeneic transplantations of hematopoietic stem cells in placental-blood unites stored at the New York Blood Center. Confirmation of...

  • High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Tanimoto, T E; Kusumi, E; Hamaki, T; Yuji, K; Ueyama, J; Miyakoshi, S; Morinaga, S; Kami, M; Kanda, Y; Ando, T; Yoshihara, S; Masuo, S; Kim, S-W; Nakai, K; Tobinai, K; Tanosaki, R; Mineishi, S; Takaue, Y; Muto, Y // Bone Marrow Transplantation;Jul2003, Vol. 32 Issue 2, p131 

    Summary:The possible advantage of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a graft-versus-lymphoma effect. We explored the feasibility and efficacy of allo-HSCT with reduced-intensity (RI) regimens in advanced malignant lymphoma (ML). A total of 20 patients with indolent...

  • Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. Avivi, I; Canals, C; Vernant, J-P; Wulf, G; Nagler, A; Hermine, O; Petersen, E; Yakoub-Agha, I; Craddock, C; Schattenberg, A; Niederwieser, D; Thomson, K; Blaise, D; Attal, M; Pfreundschuh, M; Passweg, J; Russell, N; Dreger, P; Sureda, A // Bone Marrow Transplantation;May2014, Vol. 49 Issue 5, p671 

    The objective of this retrospective analysis was to compare outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who received either a matched sibling (sib) or an unrelated donor (URD) allogeneic hematopoietic cell transplantation (allo-HCT). Long-term outcome of 172 DLBCL patients...

  • Stem Cell Transplantation for Indolent Lymphoma. Besley, Caroline; Le Dieu, Rifca // Current Medical Literature: Leukemia & Lymphoma;2014, Vol. 22 Issue 2, p33 

    The article investigates the viability of hematopoietic stem cell transplantation (HSCT) as a treatment strategy for indolent lymphoma. Topics discussed include the various therapeutic options for indolent lymphoma, and the need for accurate assessment of patients prior to declaring eligibility...

  • The EBMT activity survey: 1990-2010. Passweg, J R; Baldomero, H; Gratwohl, A; Bregni, M; Cesaro, S; Dreger, P; Witte, T de; Farge-Bancel, D; Gaspar, B; Marsh, J; Mohty, M; Peters, C; Tichelli, A; Velardi, A; de Elvira, C Ruiz; Falkenburg, F; Sureda, A; Madrigal, A // Bone Marrow Transplantation;Jul2012, Vol. 47 Issue 7, p906 

    A total of 654 centers from 48 countries were contacted for the 2010 survey. In all, 634 centers reported a total of 33 362 hematopoietic SCT (HSCT) with 30 012 patients receiving their first transplant (12 276 allogeneic (41%) and 17 736 autologous (59%)). Main indications were leukemias: 9355...

  • Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. Paralkar, V R; Nasta, S D; Morrissey, K; Smith, J; Vassilev, P; Martin, M E; Goldstein, S C; Loren, A; Rook, A H; Kim, E J; Porter, D L // Bone Marrow Transplantation;Jul2012, Vol. 47 Issue 7, p940 

    Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas that are considered incurable. The role of allogeneic hematopoietic SCT (HSCT) in the treatment of CTCL is not well defined but may provide potent graft-vs-lymphoma (GVL) activity independent of the conditioning...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics